Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

Rockefeller University

Status

Terminated

Conditions

Psoriasis

Obesity

Treatments

Procedure: Adipose tissue biopsy (fat biopsy)

Study type

Observational

Funder types

Other

Identifiers

NCT01856647

JUG-0799

Details and patient eligibility

About

Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and risk factor for type 2 diabetes and the metabolic syndrome, often linked to cardiovascular disease, certain cancers and inflammatory diseases.The phenotyping of subcutaneous adipose tissue (SAT) hematopoetic cells from obese subjects by flow cytometry, microscopy and gene expression will enable us to identify inflammation in this tissue and may help us to understand the causes and consequences of obesity in order to determine how these cells might be implicated in the initiation and/or progression of the aforementioned diseases.

Full description

Obesity is an insulin resistance-associated metabolic disorder which is a hallmark of and risk factor for type 2 diabetes and the metabolic syndrome. It is also often linked to cardiovascular disease, certain cancers (e.g., colorectal, esophageal, endometrial, and ovarian), and inflammatory diseases (e.g., psoriasis, osteoarthritis,inflammatory bowel disease).The phenotyping of subcutaneous adipose tissue (SAT) hematopoetic cells from obese subjects by flow cytometry, microscopy and gene expression will enable us to identify inflammation in this tissue and may help us to understand the causes and consequences of obesity in order to determine how these cells might be implicated in the initiation and/or progression of the aforementioned diseases.

Enrollment

1 patient

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Psoriatic lean cohort (BMI between 18-24.9 Kg/m2): moderate to severe plaque-type, at least 5% of BSA
Psoriatic obese cohort (BMI between 30-40 Kg/m2): moderate to severe plaque-type, at least 5% of BSA
Lean/non-psoriatic cohort: BMI between 18-24.9 Kg/m2
Overweight/obese non-psoriatic cohort: BMI between 30-40 Kg/m2
Subjects must be 18-65 years of age

Exclusion criteria

Having received any systemic treatment for psoriasis within the last 30 days
history of bleeding disorder
weight loss of 10 pounds in the last four weeks
current smoker
Known diagnosis of any unrelated autoimmune disease or inflammatory disease ( i.e. lupus, atopic dermatitis, rheumatoid arthritis).
Currently taking NSAIDS, aspirin, (if > once a week, stopped <30 days ago). Aspirin 81mg may be permitted if the Framingham Risk Score is < 10
Having received any anti-inflammatory medication within the last 30 days
Current use of any anti-coagulants
LFTs > 2 x upper normal limits
HIV infection
Pregnant
Less than 6 weeks post partum
history of cardiovascular disease (MI, CHF, CVA)
Any cancer diagnosis within the last 5 years
Symptoms of acute illness such as upper respiratory infection, bronchitis, gastroenteritis, or fever within 3 days of Visit 1
Any medical, psychological or social condition that, in the opinion of the Investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data
ingestion of DHA or fish oil within last 90 days
hypertension as defined as > 140 systolic and > 90 diastolic after 10 minutes of resting on 2 antihypertensives
Use of statins within the last 30 days